Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and paclitaxel

Cancer Investigation

Volumn 30, Issue 1, 2012, Pages 27-37

  Giussani, P ^a   Bassi, R ^a   Anelli, V ^a,b   Brioschi, L ^a   De Zen, F ^a   Riccitelli, E ^a   Caroli, M ^c   Campanella, R ^d   Gaini, S M ^c   Viani, P ^a   Riboni, L ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

Autophagy; Ceramide; Glioblastoma; Glucosylceramide synthase; Temozolomide

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CERAMIDES; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GLIOBLASTOMA; GLUCOSYLTRANSFERASES; HUMANS; PACLITAXEL;

EID: 84855837829     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.629379     Document Type: Article

References (50)

1. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD, Nakazato Y, Plate KH, Giangaspero F, von Deimling A, Ohgaki H, CavaneeWK. Glioblastoma. InWHO Classification of Tumours of the Central Nervous System, N Louis, H Ohgaki,OD Wiestler,WK Cavanee (eds.). Lyon: IARC Press, 2007, 33-47.
2. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
3. Reardon DA, Richm JN, Friedman HS, Bigner DD. Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 2006;24:1253-1265. (Pubitemid 46622028)
4. Grzmil M, Hemmings BA. Deregulated signalling networks in human brain tumours. Biochim Biophys Acta 2010;1804: 476-483.
5. Ogretmen B,Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004;4:604-616.
6. Gouazé-Andersson V, Cabot MC. Glycosphingolipids and drug resistance. Biochim Biophys Acta 2006;1758:2096-2110.
7. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169-180. (Pubitemid 38317287)
8. Oskouian B, Saba JD. Cancer treatment strategies targeting sphingolipid metabolism. Adv Exp Med Biol 2010;688:185-205.
9. Ponnusamy S, Meyers-Needham M, Senkal CE, Saddoughi SA, Sentelle D, Selvam SP, Salas A, Ogretmen B. Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance. Future Oncol 2010;6: 1603-1624.
10. Riboni L, Campanella R, Bassi R, Villani R, Gaini SM, Martinelli- Boneschi F, Viani P, Tettamanti G. Ceramide levels are inversely associatedwith malignant progression of human glial tumors.Glia 2002;39:105-113. (Pubitemid 34817051)
11. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347-357. (Pubitemid 32229379)
12. Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004;5:375-382. (Pubitemid 38559347)
13. Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 2009;64:647-655.
14. HermissonM, Klumpp A, WickW, Wischhusen J, NagelG, Roos W, Kaina B,WellerM.O6-methylguanineDNAmethyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006;96:766-776.
15. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
16. Bobola MS, Varadarajan S, Smith NV, Ryan D, Goff RD, Kolstoe DD, Blank A, Gold B, Silber JR. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin Cancer Res 2007;13:612-620. (Pubitemid 46225368)
17. Wang TH, Wang HS, Soong YK. Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000;88:2619-2628.
18. Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, Zhang L, Conrad C, Bogler O, Mills G, Sawaya R, Kondo S. Monitoring autophagy in glioblastoma with antibody against isoform B of humanmicrotubule-associated protein 1 light chain 3. Autophagy 2008;4:467-475. (Pubitemid 351705143)
19. Das A, Banik NL, Ray SK. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 2008;87:9-22.
20. Sur P, Sribnick EA, Patel SJ, Ray SK, Banik NL. Dexamethasone decreases temozolomide-induced apoptosis in human glioblastoma T98G cells. Glia 2005;50:160-167. (Pubitemid 40695269)
21. Gouazé V, Yu JY, Bleicher RJ, Han TY, Liu YY, Wang H, Gottesman MM, Bitterman A, Giuliano AE, Cabot MC. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy.Mol CancerTherapeut 2004;3:633-639. (Pubitemid 39193742)
22. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, Kok JW. MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 2004;110:511-522. (Pubitemid 38658016)
23. Bassi R, Giussani P, Anelli V, Colleoni T, PedrazziM, Patrone M, Viani P, SparatoreB,Melloni E, Riboni L. HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration. J Neurooncol 2008;87:23-33.
24. Bobola MS, Silber JR, Ellenbogen RG,Geyer JR, Blank A,Goff RD. O6-methylguanine-DNA methyltransferase, O6-benzylguanine, and resistance to clinical alkylators in pediatric primary brain tumor cell lines. Clin Cancer Res 2005;11:2747-2755. (Pubitemid 40569477)
25. Riboni L, Viani P, Bassi R, Stabilini A, Tettamanti G. Biomodulatory role of ceramide in basic fibroblast growth factor-induced proliferation of cerebellar astrocytes in primary culture. Glia 2000;32:137-145.
26. Riboni L, Viani P, Tettamanti G. Estimating sphingolipid metabolism and trafficking in cultured cells using radiolabeled compounds. Meth Enzymol 2000;311:656-682. (Pubitemid 29512794)
27. Viani P, Giussani P, Brioschi L, Bassi R, Anelli V, Tettamanti G, Riboni L. Ceramide in nitric oxide inhibition of glioma cell growth: evidence for the involvement of ceramide traffic. J Biol Chem 2003;278:9592-9601. (Pubitemid 36800454)
28. Ramstedt B, Leppimaki P, AxbergM, Slotte JP. Analysis of natural and synthetic sphingomyelins using high-performance thin-layer chromatography. Eur J Biochem 1999;266:997-1002. (Pubitemid 30010117)
29. Abe A, Inokuchi J, Jimbo M, Shimeno H, Nagamatsu A, Shyman JA, Shukla GS, Radin NS. Improved inhibitors of glucosylceramide synthase. J Biochem (Tokyo) 1992;111:191-196.
30. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11:448-457. (Pubitemid 38489422)
31. KabeyaY,Mizushima N, Ueno T, YamamotoA, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000;19:5720-5728.
32. HartMG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database Syst Rev 2010;1:1-23.
33. Ogretmen B, Pettus BJ, Rossi MJ, Wood R, Usta J, Szulc Z, Bielawska A, Obeid LM, Hannun YA. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line: role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem 2002;277:12960-12969. (Pubitemid 34952664)
34. Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE, Cabot MC. Metabolism of short-chain ceramide by human cancer cells - implications for therapeutic approaches. Biochem Pharmacol 2010;80:308-315.
35. Shabbits JA, Mayer LD. Intracellular delivery of ceramide lipids via liposomes enhances apoptosis in vitro. Biochim Biophys Acta 2003;1612:98-106. (Pubitemid 36555692)
36. Bieberich E, Freischutz B, Suzuki M, Yu RK.Differential effects of glycolipid biosynthesis inhibitors on ceramide-induced cell death in neuroblastoma cells. J Neurochem 1999;72:1040-1049. (Pubitemid 29085018)
37. Abe A, Wild SR, Lee WL, Shayman JA. Agents for the treatment of glycosphingolipid storage disorders. Curr Drug Metab 2001;2:331-338. (Pubitemid 32782800)
38. Makino A, Ishii K, Murate M, Hayakawa T, Suzuki Y, Suzuki M, Ito K, Fujisawa T, Matsuo H, Ishitsuka R, Kobayashi T. D-threo- 1-phenyl-2- decanoylamino-3-morpholino-1-propanol alters cellular cholesterol homeostasis by modulating the endosome lipid domains. Biochem (Moscow) 2006;45:4530-4541.
39. Dumitru CA, Weller M, Gulbins E. Ceramide metabolism determines glioma cell resistance to chemotherapy. J Cell Physiol 2009;221:688-695.
40. Wojtal KA, de Vries E, Hoekstra D, van Ijzendoorn SCD. Efficient trafficking of MDR1/P-glycoprotein to apical canalicular plasma membranes in HepG2 cells requires PKA-RII anchoring and glucosylceramide. Mol Biol Cell 2006;17:3638-3650. (Pubitemid 44156455)
41. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res 2002;8:2725-2734. (Pubitemid 34856362)
42. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol 2002;3:397-406. (Pubitemid 36958270)
43. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H,Weller M,WickW. Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 2008;14:2900-2908.
44. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004;4:296-307. (Pubitemid 38525285)
45. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulateMGMT activity. J Clin Oncol 2008;26:4189-4199.
46. Parkinson JF, Wheeler HR, Clarkson A, McKenzie CA, Biggs MT, Little NS, Cook RJ, Messina M, Robinson BG, McDonald KL. Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol 2008;87:71-78.
47. Lefranc F, Facchini V, Kiss R. Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007;12:1395-1403.
48. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741-752. (Pubitemid 47312826)
49. M?egalizzi V,MathieuV,Mijatovic T, Gailly P,Debeir O,DeNevez N, Van Damme M, Bontempi G, Haibe-Kains B, Decaestecker C, Kondoy Y, Kiss R, Lefranc F. 4-IBP, a s1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia 2007;9:358-369. (Pubitemid 46799979)
50. Pattingre S, Bauvy C, Levade T, Levine B, Codogno P. Ceramideinduced autophagy: To junk or to protect cells? Autophagy 2009;5:558-560